Protocols for Prevention of PPH During CS in High Risk Group

Different Protocols for Prevention of Atonic Postpartum Hemorrhage During Cesarean Delivery in High Risk Group

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05099575

Enrollment

448

Registered

2021-10-29

Start date

2021-10-30

Completion date

2022-10-30

Last updated

2021-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atonic PPH

Brief summary

PPH is one of the most leading causes of maternal mortality,. It means loss of 500 ml blood after vaginal delivery and 1000 ml blood after cesarean delivery. Although it's preventable it represents about 27%of maternal deaths. Atony is the main cause of PPH. 70%of PPH corresponds to uterine atony. Uterotonics like oxytocin, misoprostol, ergometrine, carbetocin and combinations of these drugs can be used but until now there is no agreement on medication that can be the most effective.

Interventions

DRUGSyntocinon, papal, misotac

Using different drugs to prevent atonic PPH during CD in high risk group

Study design

Observational model

CASE_CROSSOVER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

19 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* 1\. Pregnant full term\>37 w 2. Maternal age 19- 40 3.physical state 1&2 4.patient willing to enter the study

Exclusion criteria

* 1.who refuse to participate in study 2.immunocomprmized and patients who had contraindicated from any of drugs used 3.patients with hypersensitivity to any drug

Design outcomes

Primary

Measure	Time frame	Description
Amount of blood loss	1 year	Decrease amount of blood loss

Secondary

Measure	Time frame
Finding the drug most effective with least adverse effects	1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026